4.2 Review

Role of protein phosphorylation in cell signaling, disease, and the intervention therapy

期刊

MEDCOMM
卷 3, 期 4, 页码 -

出版社

WILEY
DOI: 10.1002/mco2.175

关键词

cell signaling; diseases; intervention therapy; protein kinases; protein phosphorylation

资金

  1. National Natural Science Fund [82004110, 81774089]
  2. Jiangsu Province Key Research and Development Program [BE2020758, BE2019637]
  3. Xuzhou Clinical Medicine Expert Team Project [2018TD004]

向作者/读者索取更多资源

Protein phosphorylation is an important post-transcriptional modification involved in a wide range of intracellular signaling pathways. Many drugs targeting protein phosphorylation have been developed for the treatment of various diseases. This review analyzed small-molecule protein phosphorylation kinase inhibitors and classified them into different groups and families, providing insights into their regulatory network and roles in disease intervention.
Protein phosphorylation is an important post-transcriptional modification involving an extremely wide range of intracellular signaling transduction pathways, making it an important therapeutic target for disease intervention. At present, numerous drugs targeting protein phosphorylation have been developed for the treatment of various diseases including malignant tumors, neurological diseases, infectious diseases, and immune diseases. In this review article, we analyzed 303 small-molecule protein phosphorylation kinase inhibitors (PKIs) registered and participated in clinical research obtained in a database named Protein Kinase Inhibitor Database (PKIDB), including 68 drugs approved by the Food and Drug Administration of the United States. Based on previous classifications of kinases, we divided these human protein phosphorylation kinases into eight groups and nearly 50 families, and delineated their main regulatory pathways, upstream and downstream targets. These groups include: protein kinase A, G, and C (AGC) and receptor guanylate cyclase (RGC) group, calmodulin-dependent protein kinase (CaMK) group, CMGC [Cyclin-dependent kinases (CDKs), Mitogen-activated protein kinases (MAPKs), Glycogen synthase kinases (GSKs), and Cdc2-like kinases (CLKs)] group, sterile (STE)-MAPKs group, tyrosine kinases (TK) group, tyrosine kinase-like (TKL) group, atypical group, and other groups. Different groups and families of inhibitors stimulate or inhibit others, forming an intricate molecular signaling regulatory network. This review takes newly developed new PKIs as breakthrough point, aiming to clarify the regulatory network and relationship of each pathway, as well as their roles in disease intervention, and provide a direction for future drug development.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据